Dry eye syndrome - vicious circle mechanism of disease
DOI:
https://doi.org/10.12775/JEHS.2023.13.03.030Keywords
dry eye disease, meibomian gland dysfunction, ocular surface diseaseAbstract
The correct structure of the tear film ensures the appropriate degree of hydration of the eye surface, and has a protective and nourishing function. Irregularities in the structure of one of the three layers of the tear film can contribute to dry eye syndrome. In recent studies, scientists have focused on dysfunction of the Meibomian gland and on deficiencies in the lipid layer of the tear film, which led to the evolution of preparation complementing the tear film. Dry eye syndrome is a multifactorial disease of the ocular surface. Symptoms vary from itching, burning, irritation, eye strain and eye inflammation to potential complications that include damage to the cornea, conjunctiva, and even loss of vision. Blurred vision is a component of the definition of DSO (apart from discomfort, tear film instability, changes in tear osmolarity, changes in neurosensory and specific inflammation on the surface of the eye). Changes in the thickness of the tear film translate into changes in the breaking power of the eye. It is believed that for every 0.1 mm change in tear film thickness, there is 0.5 D in the "+" or "-" direction. The result of aberration is the lack of a sharp, dotted image.Treatment is adjusted individually for each patient, based on the underlying disease mechanism. Recent studies have shown that dry eye is an inflammatory disease that shares many characteristics with autoimmune diseases. The main goal of this work is to present an outline of epidemiology, pathogenesis, risk factors and treatment methods.
References
Craig JP, Muntz A, Wang MTM, Luensmann D, Tan J, Trave Huarte S, et al.: Developing evidence- based guidance for the treatment of dry eye disease with artificial tear supplements: A six- month multicentre, double- masked randomised controlled trial. Ocal Surf. 2021; 20: 62-69.
Pod red. Jacek Szaflik, Justyna Izdebska Basic.: Choroby aparatu ochronnego oka i rogówki. BCSC 8. Seria Basic and Clinical Science Course. Elsevier Urban & Partner, 2019.
Pod red. Anny M. Ambroziak Stanowisko Polskiej Grupy Ekspertów Akademii Powierzchni Oka. Biblioteka OPHTHA THERAPY, 2017.
Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al.: TFOS DEWS II Report Executive Summary. Oculi Surf. 2017; 15(4): 802-812.
Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD: Distribution of aqueous- deficient and evaporative dry eye in a clinic - based patient cohort: A retrospective study. Cornea. 2012; 31(5): 472-478.
Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont k, Malet F, et al.: TFOS DEWS II Epidemiology Report. Ocul Surf. 2017; 15(3): 334-365.
Czyżewska O., Ambroziak A.M., Zaleska- Żmijewska A.: Epidemiologia zaburzeń powierzchni oka- przegląd wybranych badań klinicznych. Okulistyka 2014; 3: 18-20.
Knop E., Knop N., Millar T. et al.: The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. Invest. Ophthalmol. Vis. Sci. 2011; 52 (4): 1938-1978.
Messmer E.M., Bulgen M., Kampik A.: Hyperosmolarity of the tear film in dry eye syndrome. Dev. Ophthalmol. 2010; 45: 129-138.
Chybała K., Ambroziak A., Kołodziejczyk W., Izdebska J.: Zespół suchego oka w przebiegu pierwotnej postaci zespołu Sjogrena. Okulistyka 2014; (3): 34-35.
Begley C, Simpson T, Liu H, Salvo E, Wu Z, Bradley A, et al.: Quantitative analysis of tear film fluorescence and discomfort during tear film instability and thinning. Invest Opthalmol Vis Sci. 2013; 54(4): 2645-2653.
Rębała E., Ambroziak A.M., Izdebska J.: Hormony płciowe a powierzchnia oka. Okulistyka 2014; (3):21-25.
Mark I. Golden; Jay J. Meyer; Bhupendra C. Patel.: Dry Eye Syndrome. StatPearls Publishing; 2022 Jan.
Nov 2. PMID: 29262012
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al.:TFOS DEWS II definition and classification report. Ocul Surf 2017;15:276-83.
Lijun Qian, Wei Wei.: Identified risk factors for dry eye syndrome: A systematic review and meta-analysis. PLoS One. 2022; 17(8): e0271267. PMID: 35984830 doi: 10.1371/journal.pone.0271267
Miljanovic´ B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409-415. doi:10.1016/j.ajo.2006.11.060
Debra A Schaumberg, David A Sullivan, Julie E Buring, M Reza Dana.: Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003 Aug;136(2):318-26. doi: 10.1016/s0002-9394(03)00218-6. PMID: 12888056
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510. doi:10.1016/j.jtos.2017.05.011. Published correction appears in Ocul Surf. 2019;17(4):842.
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539-574. doi:10.1016/j.jtos.2017.05.001
Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628. doi:10.1016/j.jtos.2017.05.006.
Cynthia Matossian, Marguerite McDonald, Kendall E. Donaldson.: Dry Eye Disease: Consideration for Women's Health J Womens Health (Larchmt). 2019 Apr 1; 28(4): 502–514. doi: 10.1089/jwh.2018.7041 PMID: 30694724
Hebatallah B.Mohamed, Basma N.Abd El-Hamid et al.: Current trends in pharmaceutical treatment of dry eye disease: A review. Elsevier European Journal of Pharmaceutical Sciences Volume 175, 1 August 2022, 106206. https://doi.org/10.1016/j.ejps.2022.106206
Essa L., Laughton D., Wolffsohn J.S.: Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms? Cont. Lens Anterior Eye.2018 Feb;41(1):60-68. Doi: 10.1016/j.clae.2017.07.007
Mizunoe Y, Kobayashi M, Sudo Y, Watanabe S, Yaukawa H, Natori D et al.: Trehalose protects against oxidative stress by regulating the Keapl- Nrf2 and autophagy pathways. Redox Boil. 2018; 15: 115-124.
Matsuo T, Tsuchida Y, Morimoto N.: Trehalose eye drops in treatment of dry eye syndrome. Ophthalmology. 2002; 109: 2024-2029.
Matsuo T: Trehalose versus Hyaluronian or cellulose in eyedrops for treatment of dry eye. Jpn J Ophthalomol. 2004; 48: 321-327.
Kelly K. Nichols, Gary N. Foulks, Anthony J. Bron.: The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest Ophthalmol Vis Sci. 2011 Mar; 52(4): 1922–1929. doi: 10.1167/iovs.10-6997a PMID: 21450913
Hamano T, Horimoto K, Lee M, et al.. Sodium hyaluronate eyedrops enhance tear film stability. Jpn J Ophthalmol 1996;40:62–5.
Bron AJ, Yokoi N, Gafney E, et al.. Predicted phenotypes of dry eye: proposed consequences of its natural history. Ocul Surf 2009;7:78–92. 10.1016/S1542-0124(12)70299-9
Schaumberg DA, Nichols JJ, Papas EB et al.: The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci 2011;52:1994–2005. 10.1167/iovs.10-6997e
Sullivan BD Evans JE Dana MR Sullivan DA . Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. Arch Ophthalmol. 2006;124:1286–1292.
Kazuo Tsubota.: Short Tear Film Breakup Time-Type Dry Eye. Invest Ophthalmol Vis Sci 2018 Nov 1;59(14):DES64-DES70. DOI: 10.1167/iovs.17-23746 PMID: 30481808
Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151:792–798.
Mark S. Milner,Kenneth A. Beckman, Jodi I. Luchs et al.:Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017 Jan; 28(Suppl 1): 3–47. doi: 10.1097/01.icu.0000512373.81749.b7 PMID: 28099212
Koktekir B.E, Bozkurt B., Gonul S. et al: Effect of religious fasting on tear osmolarity and ocular surface. Eye Contact Lens 2014; 40.
Lindsley K, Matsumura S, Hatef E, Akpek EK: Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012 (5).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Ewelina Dybała, Izabela Dybała-Przygrodzka, Artur Aghadi, Iwona Cuber, Edyta Białowąs, Magdalena Mazurek
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1192
Number of citations: 0